Navigation Links
New Report Defines Challenges for New Entrants in Key Rheumatology Markets
Date:4/7/2009

MedPredict's Rheumatology Thought Leader Panel Creates a 'Fantasy Formulary' For 2015

SCOTTSDALE, Ariz., April 7 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis, lupus, gout and psoriatic arthritis.

To develop this analysis, entitled "Thought Leader Insight & Analysis: Rheumatology," MedPredict conducted a thought exercise with four North American and four European rheumatologists. The purpose was to identify their "must have" branded and generic drugs for their real-world practices in the year 2015. This report outlines each panelist's "Fantasy Formulary," and the strengths, weaknesses and product news for each pharmacotherapy that is mentioned.

"It is essential that drug developers consider the entire rheumatology practice when establishing their strategies going forward," according to Dr. Jeffrey Berk, MedPredict's president and one of the report's authors. "One key insight from our research is that drugs which will be beneficial across multiple indications are going to have an easier time getting on formulary."

The report will answer the following questions:

  • What are these thought leaders' top ten choices for their rheumatology practice in 2015?
  • How do their choices differ by geography, and why?
  • How will the availability of biosimilars for substitution of first generation biologics impact the environment for new entrants?
  • What is the preferred anti-TNF drug, and why?
  • Where will new mechanistic approaches, such as Jak and Syk inhibitors, IL-17, anti-B-cell, and others fit in the rheumatologist's armamentarium?

Companies/Partnerships mentioned in this report include: Abbott, Alder, Amgen, Amgen/Wyeth, Biogen Idec, Bristol-Myers Squibb, Can-Fite, Centocor, Centocor/Schering-Plough, Chelsea, GlaxoSmithKline/Genmab, Human Genome Sciences, Incyte, J&J/Alza, Lilly, Medarex, Merck, Merck Serono/ZymoGenetics, Mitsubishi Tanabe, Neovacs, Nitec/SkyePharma, Novartis, Pozen/AstraZeneca, Rigel, Roche, Roche/Chugai, Roche/Genentech/Biogen Idec, Sanofi-Aventis, Savient, Takeda, UCB, Vertex, and Wyeth/Trubion.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pain in the ICU report suggests comprehensive approach
2. Photos: Report Shows Youth Health Educators Reach More Poor Teens with a Message of Living Healthy Lives!
3. Chronic Pain Sufferers Report Relief: DRJ Group Teams With Adult Foster Care Facilities to Evaluate Effectiveness of Stopain Topical Analgesic
4. Hazardous Health Plans: Consumer Reports Investigation Finds Serious Gaps in Individual Health Insurance Policies
5. Consumer Reports Survey: Hands-On Therapies Among Top-Rated Treatments for Back Pain
6. U.S. Adults Needlessly Vulnerable to Vaccine-Preventable Diseases, According to New Report
7. MGT Capital Investments, Inc. Reports Fiscal 2008 Financial Results and Provides an Update on Recent Developments
8. IDM Pharma Complies With NASDAQ Marketplace Rule 4350(b)(1)(B) and Announces Filing of Annual Report on Form 10-K for 2008 Fiscal Year Containing Audit Opinion With Going Concern Qualification
9. Allscripts Reports Fiscal 2009 Third Quarter Results
10. J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members
11. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , ... May 27, 2016 , ... This campaign aims ... stroke, which we as a society can control and change. , As nearly 795,000 ... every 40 seconds within the United States. Plus, with an estimated 129,000 of these ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... interest stories, courtesy of leaders in the nursing and health care industry. It ... leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... St. Louis, Missouri (PRWEB) , ... May 26, ... ... optimal cost, quality and clinical outcomes, hosted members and suppliers for its inaugural ... with a focus on their mission of elevating the operational health of America’s ...
(Date:5/26/2016)... ... ... The Woodlands at John Knox Village , Florida’s first Life Plan ... and healing, celebrated its grand opening, today. The Woodlands at John Knox Village is ... Staff. , “This is an incredibly fulfilling time for John Knox Village as we ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... May 24, 2016  Diana Russell suffers from a ... from the inside out.  This disease has put her ... her children and grandchildren to leave her home.  Because ... family cannot haul the wheelchair.  So if there is ... and Diana is left to wait for the bus. ...
(Date:5/24/2016)...  Joe Marziani has joined VMS BioMarketing as senior vice president of sales, announced ... new role, Marziani will lead the company,s business development and sales team, exploring new ... Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology: